W. Herz

Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.

R. Greil, T. Nielsen, S. Ferree, 2014 .

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial

R. Greil, S. Ferree, C. Schaper, 2021, The British journal of surgery.

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort.

R. Greil, M. Gnant, C. Dreezen, 2020, ESMO open.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

R. Greil, M. Gnant, H. Samonigg, 2015, British Journal of Cancer.